» Articles » PMID: 29336904

Bypass Versus Endovascular Intervention for Healing Ischemic Foot Wounds Secondary to Tibial Arterial Disease

Overview
Journal J Vasc Surg
Publisher Elsevier
Date 2018 Jan 17
PMID 29336904
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Pedal (inframalleolar) bypass is a long-standing therapy for tibial arterial disease in patients with ischemic tissue loss. Endovascular tibial intervention is an appealing alternative with lower risks of perioperative mortality or complications. Our objective was to compare the effectiveness of these two treatment modalities with respect to patency and limb-related clinical outcomes.

Methods: We performed a retrospective chart review of patients presenting between 2006 and 2013 with ischemic foot wounds and infrapopliteal arterial disease who underwent a revascularization procedure (either open surgical bypass to an inframalleolar target or endovascular tibial intervention). Data were collected on baseline demographics and comorbidities, procedural details, and postprocedure outcomes. The primary outcome was successful healing of the index wound, with mortality, major amputation, and patency assessed as secondary outcomes.

Results: We identified 417 patients who met our eligibility criteria; 105 underwent surgical bypass and 312 underwent endovascular intervention, with mean follow-up of 25.0 and 20.2 months, respectively (P = .08). The endovascular patients were older at baseline (P = .009), with higher rates of hyperlipidemia (P = .02), prior cerebrovascular accidents (P = .04), and smoking history (P = .04). Within 30 days postoperatively, there was no difference in mortality (P = .31), but bypass patients had longer hospital length of stay (P < .0001), higher rate of discharge to nursing facility (P < .001), and higher rates of myocardial infarctions (P = .03) and wound complications (P < .001). At 6 months, the rate of wound healing was 22.4% in the bypass group compared with 29.0% in the endovascular group (P = .02). At 1 year, survival was higher after bypass (86.2% vs 70.4%; P < .0001), but freedom from major amputation was similar (84.9% vs 82.8%; P = .42). Primary patency (53.1% vs 38.2%; P = .002) and primary assisted patency (76.6% vs 51.7%; P < .0001) were higher in the bypass group, but there was no difference in secondary patency (77.3% vs 73.8%; P = .13).

Conclusions: Endovascular tibial intervention is associated with poorer primary patency but similar secondary patency and wound healing rates compared with the "gold standard" of surgical bypass to a pedal target. In patients with tibial arterial disease, endovascular intervention should be considered a lower risk alternative to pedal bypass that provides similar clinical outcomes.

Citing Articles

Endovascular revascularization vs. open surgical revascularization for patients with lower extremity artery disease: a systematic review and meta-analysis.

Shu H, Xiong X, Chen X, Sun X, Zhang R, Wang R Front Cardiovasc Med. 2023; 10:1223841.

PMID: 37554365 PMC: 10405177. DOI: 10.3389/fcvm.2023.1223841.


Principal predictors of major adverse limb events in diabetic peripheral artery disease: A narrative review.

Biscetti F, Cecchini A, Rando M, Nardella E, Gasbarrini A, Massetti M Atheroscler Plus. 2023; 46:1-14.

PMID: 36643723 PMC: 9833249. DOI: 10.1016/j.athplu.2021.10.003.


The short- and long-term efficacies of endovascular interventions for the treatment of acute ischemic stroke patients.

Yang X, Jia X, Ren H, Zhang H Am J Transl Res. 2021; 13(5):5436-5443.

PMID: 34150141 PMC: 8205676.


The Global Anatomic Staging System Does Not Predict Limb Based Patency of Tibial Endovascular Interventions.

Hicks C, Zhang G, Canner J, Weaver M, Lum Y, Black J Ann Vasc Surg. 2021; 75:79-85.

PMID: 33905854 PMC: 9807072. DOI: 10.1016/j.avsg.2021.04.007.

References
1.
Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A . Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2014; 131(5):495-502. PMC: 4323569. DOI: 10.1161/CIRCULATIONAHA.114.011004. View

2.
Krzanowski M, Drelicharz L, Belowski A, Partyka L, Sumek-Brandys B, Ramakrishnan P . Costs of Real-Life Endovascular Treatment of Critical Limb Ischemia: Report from Poland-A European Union Country with a Low-Budget Health Care System. Ann Vasc Surg. 2015; 31:111-23. DOI: 10.1016/j.avsg.2015.08.016. View

3.
Giaquinta A, Vincenzo A, De Marco E, Veroux M, Veroux P . Everolimus-Eluting Stent for Patients With Critical Limb Ischemia and Infrapopliteal Arterial Occlusive Disease. Vasc Endovascular Surg. 2017; 51(2):60-66. DOI: 10.1177/1538574416689429. View

4.
Conte M . Diabetic revascularization: endovascular versus open bypass--do we have the answer?. Semin Vasc Surg. 2012; 25(2):108-14. DOI: 10.1053/j.semvascsurg.2012.04.004. View

5.
Popplewell M, Davies H, Jarrett H, Bate G, Grant M, Patel S . Bypass versus angio plasty in severe ischaemia of the leg - 2 (BASIL-2) trial: study protocol for a randomised controlled trial. Trials. 2016; 17:11. PMC: 4704263. DOI: 10.1186/s13063-015-1114-2. View